The FDA granted Breakthrough Therapy Designation on August 4, 2025 to DYNE-251, Dyne Therapeutics' investigational drug for Duchenne muscular dystrophy in boys whose mutations are amenable to exon 51 skipping, Parent Project Muscular Dystrophy reported.
The designation is meant to speed development and review when early data suggest a drug may substantially improve on available therapy. For families of the roughly 13% of Duchenne patients with exon 51-amenable mutations, it put a new option on a faster track.
What the designation was based on
The designation rested on the Phase 1/2 DELIVER trial, where patients showed sustained functional improvements such as faster time to rise and improved walking speed over 18 months, according to Parent Project MD. It brings extra FDA guidance and eligibility for rolling and priority review, CureDuchenne noted.
It was the company's second breakthrough designation of the year. Its myotonic dystrophy type 1 drug, DYNE-101, had received one earlier in 2025, Dyne said.
How the drug works
DYNE-251 links a phosphorodiamidate morpholino oligomer, the same class of molecule used in existing exon-skipping drugs, to an antibody fragment that binds the transferrin receptor 1 on muscle cells. The goal is to get more of the drug into muscle so cells can make near full-length dystrophin.
Update, November 2026: an FDA decision is due in January
- The drug was renamed zeleciment rostudirsen (z-rostudirsen).
- Japan's health ministry granted it orphan drug designation on September 29, 2025, Dyne announced.
- Dyne submitted a Biologics License Application on May 26, 2026, seeking accelerated approval based on dystrophin as a surrogate endpoint, with a proposed dose of 20 mg/kg given intravenously every 4 weeks.
- The FDA accepted the application with Priority Review and set a target action date of January 21, 2027, Dyne announced on July 20, 2026.
- A confirmatory Phase 3 trial is under way, as accelerated approval requires.
Why it matters for students and residents
Duchenne is a staple of pediatrics, neurology and board exams. Accelerated approval on a surrogate endpoint such as dystrophin is a recurring debate: the drug reaches patients sooner, but clinical benefit must still be confirmed. Expect that tension to come up on rounds. More in MedRise Medical News and our Shelf Prep guides.
January 21, 2027 is the date to watch for families, clinicians and the trainees who will care for these patients.
MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.

